Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Abstract

Povorcitinib demonstrated efficacy in HS, with no evidence of increased incidence of adverse events among doses.